Please use this identifier to cite or link to this item:
Title: Radiation recall dermatitis induced by pazopanib.
Austin Authors: Azad, Arun A;Maddison, Claire;Stewart, Josephine
Affiliation: Joint Austin-Ludwig Oncology Unit, Austin Health, Melbourne, Australia
Issue Date: 14-Oct-2013
Publication information: Onkologie 2013; 36(11): 674-6
Abstract: Pazopanib is a multi-targeted tyrosine kinase inhibitor that has recently been approved for treatment of advanced clear cell renal cell carcinoma (RCC). There are no previous reports of pazopanib triggering radiation recall dermatitis (RRD).A 60-year-old male patient was commenced on pazopanib for metastatic RCC 2 weeks prior to receiving radiotherapy (10×30 Gy) to bone metastases at the T9 and L4 vertebrae and right mid-shaft of humerus. Although there were no immediate complications from radiotherapy, 2 weeks after finishing radiation he developed a pruritic, erythematous, maculo-papular rash localized to the T9 and right humeral radiotherapy fields. The patient was diagnosed with RRD induced by pazopanib and commenced on a course of oral prednisolone, which resulted in resolution of his rash. He has now completed 5 months of pazopanib with no recurrence of RRD.We report the first case of RRD triggered by pazopanib. With increasing use of pazopanib for advanced RCC, clinicians must be aware of the possibility that RRD can occur in patients treated with this agent following radiotherapy.
Gov't Doc #: 24192773
DOI: 10.1159/000355649
Type: Journal Article
Subjects: Carcinoma, Renal Cell.complications.therapy
Chemotherapy, Adjuvant.adverse effects
Combined Modality Therapy.methods
Kidney Neoplasms.complications.therapy
Middle Aged
Pyrimidines.adverse effects.therapeutic use
Radiodermatitis.etiology.prevention & control
Radiotherapy, Conformal.adverse effects
Sulfonamides.adverse effects.therapeutic use
Treatment Outcome
Appears in Collections:Journal articles

Show full item record

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.